Dimensional Fund Advisors’s RAPT Therapeutics RAPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-8,934
| Closed | -$302K | – | 3278 |
|
|
2025
Q4 | $302K | Hold |
8,934
| – | – | ﹤0.01% | 3041 |
|
|
2025
Q3 | $231K | Buy |
+8,934
| New | +$117K | ﹤0.01% | 3105 |
|
|
2025
Q2 | – | Sell |
-8,944
| Closed | -$87.3K | – | 3320 |
|
|
2025
Q1 | $87.3K | Sell |
8,944
-9,659
| -52% | -$95K | ﹤0.01% | 3215 |
|
|
2024
Q4 | $235K | Sell |
18,603
-13,154
| -41% | -$167K | ﹤0.01% | 3141 |
|
|
2024
Q3 | $511K | Sell |
31,757
-9,728
| -23% | -$197K | ﹤0.01% | 3036 |
|
|
2024
Q2 | $1.01M | Sell |
41,485
-28,116
| -40% | -$1.3M | ﹤0.01% | 2907 |
|
|
2024
Q1 | $5M | Buy |
69,601
+8,565
| +14% | +$1.19M | ﹤0.01% | 2549 |
|
|
2023
Q4 | $12.1M | Sell |
61,036
-12,406
| -17% | -$1.54M | ﹤0.01% | 2234 |
|
|
2023
Q3 | $9.76M | Buy |
73,442
+5,844
| +9% | +$954K | ﹤0.01% | 2274 |
|
|
2023
Q2 | $10.1M | Buy |
67,598
+10,395
| +18% | +$1.62M | ﹤0.01% | 2252 |
|
|
2023
Q1 | $8.4M | Buy |
57,203
+3,893
| +7% | +$787K | ﹤0.01% | 2296 |
|
|
2022
Q4 | $8.44K | Buy |
53,310
+15,938
| +43% | +$2.55M | ﹤0.01% | 2271 |
|
|
2022
Q3 | $7.19M | Buy |
37,372
+1,835
| +5% | +$347K | ﹤0.01% | 2293 |
|
|
2022
Q2 | $5.19M | Sell |
35,537
-129
| -0.4% | -$17.2K | ﹤0.01% | 2435 |
|
|
2022
Q1 | $6.27M | Buy |
35,666
+8,655
| +32% | +$1.63M | ﹤0.01% | 2472 |
|
|
2021
Q4 | $7.94M | Buy |
27,011
+13,069
| +94% | +$3.49M | ﹤0.01% | 2394 |
|
|
2021
Q3 | $3.46M | Buy |
13,942
+11,329
| +434% | +$3M | ﹤0.01% | 2682 |
|
|
2021
Q2 | $665K | Buy |
+2,613
| New | +$488K | ﹤0.01% | 3104 |
|
Dimensional Fund Advisors's RAPT Position: Q1 2026 in Review
Dimensional Fund Advisors sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 8,934 shares — an estimated $302K sold.
Dimensional Fund Advisors first reported a position in RAPT in Q2 2021 and held it in 18 quarters. The position peaked at $12.1M in Q4 2023. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.
- Dimensional Fund Advisors reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
- Dimensional Fund Advisors sold 8,934 RAPT Therapeutics shares in Q1 2026, an estimated $302K.
- Dimensional Fund Advisors first reported a position in RAPT Therapeutics in Q2 2021 and held it in 18 quarters.
- Dimensional Fund Advisors's RAPT Therapeutics position peaked at $12.1M in Q4 2023.
- 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.
Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.